

Virus-like particles of SARS-CoV2

Catalog Number: AG1900B/Lot# 052016CCG

Strength: 0.1mg


Accession: YP_009724390, YP_009724392, YP_009724393, YP_009724397

Specifications and Use


Description

The virus-like particles (VLPs) of SARS-CoV2 were expressed in Sf21 cells, assembled with the spike (S, Flag-tagged, Figure A), envelope (E), membrane (M) and nucleocapsid (N, 6His-tagged, Figure A) proteins of SARS-CoV2. The VLPs were purified by the combination of gradient centrifugation and chromatographic methods. Most of VLPs became nanovesicles after extensive purification as shown in Figure B. VLPs can be used for 1) antibody generation and nebulization, 2) detection of antibodies of SARS-CoV2, 3) binding assays and others.

A. Western Blot



B. Cryo-EM



Source

Sf21

Concentration

0.18mg/ml

Purity

~80%, as determined by SDS-PAGE.

Biological Activity

VLPs of SARS-CoV2 are suitable for the related assays.

Formulation

20mM Tris-Cl, pH7.9, 100mM NaCl and 0.5mM EDTA.

Storage

The protein sample can be stored under sterile conditions at -20°C to -70°C for three months without detectable loss of activity.

FOR RESEARCH USE ONLY!!!